Utvr PowerPoint PPT Presentations
All Time
Recommended
UTVR IVANJE POTREBA ZA ZDRAVSTVENOM NJEGOM Edukacijski ciljevi: objasniti prvu fazu procesa zdravstvene njege utvr ivanje potreba i njen odnos s drugim fazama ...
| PowerPoint PPT presentation | free to download
Edukacijski ciljevi Objasniti drugu fazu procesa planiranje zdravstvene njege i njen odnos s drugim fazama Objasniti utvr ivanje prioriteta u procesu zdravstvene ...
| PowerPoint PPT presentation | free to download
III glava Kalkulacija robe u trgovinskim preduze ima Kalkulacija robe u trgovinskim preduze ima Kalkulacija je metod utvr ivanja nabavne cene robe, cene ko tanja ...
| PowerPoint PPT presentation | free to download
Analiza post-mortem izvestaja Analiza post-mortem izvestaja Dam Od 72 slu aja gde je prona en samo deo tela uzrok smrti nije utvr en . Od 9 slu ajeva gde je ...
| PowerPoint PPT presentation | free to view
Title: Presentazione di PowerPoint Author: Osm Last modified by: Osm Created Date: 5/16/2005 2:33:51 PM Document presentation format: Presentazione su schermo
| PowerPoint PPT presentation | free to download
STUDY DESIGN ACS (STEMI or UA/NSTEMI) & Planned PCI N= 13,000 ASA Double-blind CLOPIDOGREL 300 mg LD/ 75 mg MD PRASUGREL 60 mg LD/ 10 mg MD Median duration of therapy ...
| PowerPoint PPT presentation | free to download
Title: OSNOVE MENAD MENTA Author: Branislav Mashic Last modified by: FBIS Created Date: 10/6/2003 6:35:38 AM Document presentation format: On-screen Show
| PowerPoint PPT presentation | free to view
Undergoing PCI ISAR-REACT 3 ... Endpoint at 30 Days Composite rate of: Death Myocardial infarction Urgent target vessel revascularization LBCT March 29, ...
| PowerPoint PPT presentation | free to download
PREVENT-ICARUS However beautiful the strategy, you should occasionally look at the results (Winston Churcill) * * * * Title: Diapositiva 1 Author:
| PowerPoint PPT presentation | free to view
Clinical Trials of GP IIb/IIIa Inhibition Major Trials of GP IIb/IIIa Inhibitors in ACS GP IIb/IIIa Inhibitors in PCI GP IIb/IIIa Inhibition in Patients With Diabetes
| PowerPoint PPT presentation | free to view
Data are presented as mean and 95% CI. PPI, proton pump inhibitor; VASP, ... administration of clopidogrel plus ASA and other standard therapies in patients ...
| PowerPoint PPT presentation | free to view
ZDRAVSTVENA NJEGA UZIMANJE STOLICE ZA PREGLED I PRETRAGE FIZIKALNI PREGLED uo avamo patolo ke promjene stolice ( sluz, krv...) stolica se mora sa uvati ( u ...
| PowerPoint PPT presentation | free to view
Title: PowerPoint Presentation Author: Nada Prlic Last modified by: Ivana Created Date: 11/9/2002 5:40:35 PM Document presentation format: On-screen Show
| PowerPoint PPT presentation | free to download
Clopidogrel in ACS and CABG Surgery Clopidogrel use and bleeding after coronary artery bypass graft surgery John Hyung-Jun Kim, MD, MBA, a,b L. Kristin Newby, MD, MHS ...
| PowerPoint PPT presentation | free to view
www.themegallery.com TJELESNA I ZDRAVSTVENA KULTURA U KOLSKOM KURIKULUMU Prijedlozi za izradu kolskog kurikuluma u osnovnoj i srednjoj koli
| PowerPoint PPT presentation | free to view
EL OBJETIVO PRIMORDIAL DEL TRATAMIENTO FISIOPATOLOGICO DEL SINDROME CORONARIO ... Ex vivo platelet aggregation for eptifibatide bolus/infusion doses in PPACK. Placebo ...
| PowerPoint PPT presentation | free to view
Emerging Antiplatelet Therapies and the Latest Clinical ... Quantify Postoperative Chest-Tube Drainage, Transfusions, and. Re-exploration. Medical Management ...
| PowerPoint PPT presentation | free to view
* * * * * * The randomized double-blind TRITON-TIMI 38 trial showed that prasugrel was superior to clopidogrel in reducing ischemic events in patients with acute ...
| PowerPoint PPT presentation | free to download
Prasugrel Compared with Clopidogrel in Patients with ST-Elevation MI Undergoing Percutaneous Coronary Intervention Gilles Montalescot, Stephen D. Wiviott, Eugene ...
| PowerPoint PPT presentation | free to view
... EL UL VaR ELT Gubitak ... U farmaceutskoj industriji n je ve i od perioda patentne za tite U ICT n je manji od perioda projekcije Razli iti ...
| PowerPoint PPT presentation | free to download
Porez na dobit - uvod Povijesni aspekt (pojava dru tava kapitala); Opravdanje postojanja (za to pdob ako postoji por. na doh. fiz. osoba?); razlozi:
| PowerPoint PPT presentation | free to download
CREDO - 1 Year Results Conclusions ... CREDO - General Conclusions ... In the CREDO trial patients received the standard of care in the US (about 50 ...
| PowerPoint PPT presentation | free to view
Anatomy. 0. 5. 10. 15. 0. 30. 60. 90. 180. 270. 360. 450 ... Male. STEMI. UA/NSTEMI. 0.5. 1. 2. Prasugrel Better. Clopidogrel Better. HR. Age. Reduction in risk ...
| PowerPoint PPT presentation | free to view
ESPRIT: Study design. Eptifibatide. 180- g/kg ... ESPRIT Investigators. ... ESPRIT: Primary outcome over time. VBWG. Lincoff AM et al. J Am Coll ...
| PowerPoint PPT presentation | free to view
Pregnancy (present or suspected) Kastrati A et al. JAMA 2006;295:1531-38. Berger ACC2006 ... Sample size estimation. Incidence of 1o end point with placebo: 12 ...
| PowerPoint PPT presentation | free to view
Title: Slide 1 Author: Tomislav Grabaric Last modified by: Prof. Ivan Ga parac Created Date: 3/1/2004 9:34:06 AM Document presentation format: On-screen Show
| PowerPoint PPT presentation | free to view
Deepak L. Bhatt, MD, MPH, A. Michael Lincoff, MD, C. Michael Gibson, MS, MD, Gregg W. Stone, MD, Steven McNulty, MS, Gilles Montalescot, MD, PhD,
| PowerPoint PPT presentation | free to download
STRATEGIJA I STRATE KO PLANIRANJE Geneza i evolucija menad menta kao procesa ostvarenja organizacionih ciljeva prolazila je kroz razli ite faze,
| PowerPoint PPT presentation | free to download
Pro-drug. Hepatic metabolism. Cytochrome P450. Active metabolite. N. S. O ... ClinicalTrials.gov Identifier: NCT00391872. Cangrelor. Intravenous P2Y12 Inhibitor ...
| PowerPoint PPT presentation | free to view
STEMI Interventional Techniques and Antithrombotic Therapy in the Cathetterization Laboratory Eli I. Lev, MD Director, Inteventional Cardiology Unit,
| PowerPoint PPT presentation | free to download
Gregg W. Stone, MD, Steven McNulty, MS, Gilles Montalescot, MD, PhD, ... Maharaj Nakorn Chiang Mai Hospital. 66. CHAMPION PLATFORM Top 10 Enrollers ...
| PowerPoint PPT presentation | free to view
Thrombus Susceptibility and the Vulnerable Plaque: ... OPUS-TIMI 16. Sabatine MS et al. Circulation. 2002;105:1760-3. TACTICS-TIMI 18. 1. 1.8 ...
| PowerPoint PPT presentation | free to view
Target therapy: more aggressive treatment in. higher-risk patients ... TIMI IIB/ESSENCE Metanalysis: Enoxaparin vs Unfractionated Heparin ...
| PowerPoint PPT presentation | free to view
Control group: UFH bolus of 175 U/kg 18-24 hr infusion ... Bolus of 140 U/kg. Placebo Infusion. Clopidogrel 75-150 mg/day until discharge (3 days) ...
| PowerPoint PPT presentation | free to view
Interventional Pharmacology: The Basics Michael J. Cowley, FACC,FSCAI Nothing to Disclose Heparin (UFH) GP IIb/IIIa Receptor Antagonists Low Molecular Weight Heparins ...
| PowerPoint PPT presentation | free to view
RESULTADOS: CARACTER STICAS BASALES. Grupos 1) TICAGRELOR 2) CLOPIDOGREL n % n % n 9333 9291 Antecedentes de enfermedad cardiaca y vascular IAM 1900
| PowerPoint PPT presentation | free to view
OSIGURANJE IZVOZNIH KREDITA Ekonomski forum mladih Dimitrije Stamenovi 08.11.2005 Beograd
| PowerPoint PPT presentation | free to download
49 yo F with a h/o HTN, HL, strong FH of CAD admitted with new onset CP ... Denied SOB, N/V, lightheadedness or diaphoresis. Courtesy of M O'Donoghue (BWH/MGH) ...
| PowerPoint PPT presentation | free to view
U. O. CARDIOLOGIA con UTIC Lamezia Terme Preparazione farmacologica alla PTCA: STEMI Negli ospedali senza emodinamica Dott. Antonio Butera Lamezia Terme
| PowerPoint PPT presentation | free to view
misnomer about bivalirudin, and. about 1-year outcomes. Insights about what to expect from novel antiplatelet therapy and what the ...
